Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Intermediate 10-year ASCVD Risk Population

• Status: Not yet recruiting
• Trial end date: 2025-12-01

Summary

Current guidelines recommend moderate-intensity lipid-lowering therapy (goal for LDL-C <2.6 mmol/L or 30%-50% reduction from baseline) for patients with intermediate 10-year ASCVD risk. In these patients, early coronary atherosclerotic plaques (luminal stenosis<50%) detected by coronary CT angiography are common, but further interventions are lacking. This study aims to analyze whether intensive lipid-lowering therapy (goal for LDL-C <1.8 mmol/L or ≥50% reduction from baseline) could delay the progression of coronary atherosclerotic lesions and reduce the adverse cardiovascular events in these target patients.

• Phase: N/A

Details

• Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital